Hip Arthroscopy
0
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Colorado TherapeuticsCO - Louisville
1 programModified hip capsule side fixed slotted cannulaN/A1 trial
Active Trials
Geistlich PharmaSwitzerland - Root
1 programAutologous matrix-induced chondrogenesisPHASE_11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Geistlich PharmaAutologous matrix-induced chondrogenesis
ArthrexHip Arthroscopy
Colorado TherapeuticsModified hip capsule side fixed slotted cannula
Clinical Trials (3)
Total enrollment: 10,151 patients across 3 trials
AMIC Compared With Microfracture for Focal Articular Cartilage Damage of the Hip
Start: Mar 2023Est. completion: Jan 202740 patients
Phase 1Recruiting
An Evaluation of Hip Preservation Outcomes
Start: Jun 2023Est. completion: Jun 205310,000 patients
N/ARecruiting
Modifications of Devices for Hip Arthroscopy
Start: Aug 2020Est. completion: Aug 2026111 patients
N/AEnrolling By Invitation
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 10,151 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.